Urologists’ and GPs’ knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands

por Cremers, Ruben, van Asperen, Christi, Kil, Paul, Vasen, Hans, Wiersma, Tjerk, van Oort, Inge, Kiemeney, Lambertus
Publicado 2011

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients

por Benoist, Guillemette E., van Oort, Inge M., Burger, David M., Mehra, Niven, van Erp, Nielka P.
Publicado 2020

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide

por Podgoršek, Eva, Mehra, Niven, van Oort, Inge M., Somford, Diederik M., Boerrigter, Emmy, van Erp, Nielka P.
Publicado 2023

Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy

por Somford, Diederik M., van Oort, Inge M., Cosyns, Jean-Pierre, Witjes, J. Alfred, Kiemeney, Lambertus A. L. M., Tombal, Bertrand
Publicado 2011

Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study

por Vlaming, Michiel, Bleiker, Eveline M. A., van Oort, Inge M., Kiemeney, Lambertus A. L. M., Ausems, Margreet G. E. M.
Publicado 2022

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer

por Slootbeek, Peter H. J., Kloots, Iris S. H., van Oort, Inge M., Kroeze, Leonie I., Schalken, Jack A., Bloemendal, Haiko J., Mehra, Niven
Publicado 2023

PREDICT: model for prediction of survival in localized prostate cancer

por Kerkmeijer, Linda G. W., Monninkhof, Evelyn M., van Oort, Inge M., van der Poel, Henk G., de Meerleer, Gert, van Vulpen, Marco
Publicado 2015

Known susceptibility SNPs for sporadic prostate cancer show a similar association with “hereditary” prostate cancer

por Cremers, Ruben G., Galesloot, Tessel E., Aben, Katja K., van Oort, Inge M., Vasen, Hans F., Vermeulen, Sita H., Kiemeney, Lambertus A.
Publicado 2015

The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited

por Cremers, Ruben G., Aben, Katja K., van Oort, Inge M., Sedelaar, J.P. Michiel, Vasen, Hans F., Vermeulen, Sita H., Kiemeney, Lambertus A.
Publicado 2016

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics

por Lubberman, Floor J. E., Benoist, Guillemette E., Gerritsen, Winald, Burger, David M., Mehra, Niven, Hamberg, Paul, van Oort, Inge, van Erp, Nielka P.
Publicado 2019

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer

por Boerrigter, Emmy, Benoist, Guillemette E., Overbeek, Joanneke K., Donders, Rogier, Mehra, Niven, van Oort, Inge M., ter Heine, Rob, van Erp, Nielka P.
Publicado 2021

Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence

por Bosch, Dianne, Kuppen, Malou C. P., Tascilar, Metin, Smilde, Tineke J., Mulders, Peter F. A., Uyl-de Groot, Carin A., van Oort, Inge M.
Publicado 2023

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

por van der Doelen, Maarten J., Stockhaus, Agnes, Ma, Yuanjun, Mehra, Niven, Yachnin, Jeffrey, Gerritsen, Winald R., Nilsson, Sten, van Oort, Inge M., Ullén, Anders
Publicado 2021

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients

por Hendriks, Rianne J., Dijkstra, Siebren, Smit, Frank P., Vandersmissen, Johan, Van de Voorde, Hendrik, Mulders, Peter F. A., van Oort, Inge M., Van Criekinge, Wim, Schalken, Jack A.
Publicado 2018

The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care—A Systematic Review

por Bokkers, Kyra, Vlaming, Michiel, Engelhardt, Ellen G., Zweemer, Ronald P., van Oort, Inge M., Kiemeney, Lambertus A. L. M., Bleiker, Eveline M. A., Ausems, Margreet G. E. M.
Publicado 2022

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

por Leyten, Gisele H. J. M., Wierenga, Elisabeth A., Michiel Sedelaar, J. P., van Oort, Inge M., Futterer, Jurgen J., Barentsz, Jelle O., Schalken, Jack A., Mulders, Peter F. A.
Publicado 2013

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide

por Benoist, Guillemette E., Hendriks, Rianne J., Mulders, Peter F. A., Gerritsen, Winald R., Somford, Diederik M., Schalken, Jack A., van Oort, Inge M., Burger, David M., van Erp, Nielka P.
Publicado 2016

Clinical implementation of pre‐biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer

por Israël, Bas, Immerzeel, Jos, van der Leest, Marloes, Hannink, Gerjon, Zámecnik, Patrik, Bomers, Joyce, Schoots, Ivo G., van Basten, Jean‐Paul, Debruyne, Frans, van Oort, Inge, Sedelaar, Michiel, Barentsz, Jelle
Publicado 2021

Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer

por Smits, Minke, Ekici, Kamer, Pamidimarri Naga, Samhita, van Oort, Inge M., Sedelaar, Michiel J. P., Schalken, Jack A., Nagarajah, James, Scheenen, Tom W. J., Gerritsen, Winald R., Fütterer, Jurgen J., Mehra, Niven
Publicado 2020

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer

por Slootbeek, Peter H. J., Kloots, Iris S. H., Smits, Minke, van Oort, Inge M., Gerritsen, Winald R., Schalken, Jack A., Ligtenberg, Marjolijn J. L., Grünberg, Katrien, Kroeze, Leonie I., Bloemendal, Haiko J., Mehra, Niven
Publicado 2021